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pen access Abstract Two simple, accurate and sensitive and techniques have been developed and validated for
the determination of yohimbine hydrochloride in presence of its acid, alkaline and photo-degradates
as stability-indicating studies. First spectrophotometric technique was adopted for the determination
of the investigated drug in presence of degradation products, by the use of derivative and derivative
ratio methods, respectively, while the second technique utilized a high-performance liquid chromatog-
raphy for the determination of yohimbine hydrochloride in presence of its degradation products, as sta-
bility indicatingmethod. The chromatographic separationwas achieved isocratically by using amobile
phase of water and methanol in a ratio of 55:45 V/V containing 0.5% triethylamine. The analysis was
carried out using C18 (4.6 · 150 mm, 5 lm) at ﬂow rate of 1.0 ml/min and UV detection at 270 nm. All
the proposed methods were validated according to the International Conference on Harmonization
(ICH) guidelines and successfully applied for determination of the drug in pure form, in laboratory pre-
paredmixtures and in pharmaceutical preparations. The obtained results were statistically compared to
the ofﬁcial method of analysis for yohimbine hydrochloride and no signiﬁcant differences were found.
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68 M. Farouk et al.1. Introduction
Yohimbine is methyl ester of 17,a-hydroxyyohimban-16,
a-carboxylic acid,1 it has kmax 279–282 nm.
2 Yohimbine
hydrochloride is the most important of the complex indole
alkaloid types, having a competitive a-adrenergic blockade
of limited duration, and also is selective for the presynaptic
a2-receptor. Recently, many authors investigated the contro-
versial aphrodisiac property of yohimbine 3–5 Clark et al.6
studied the possible effectiveness of yohimbine as an aphrodi-
siac, where it has a low oral bioavailability of about 30%.
However the clinical use of yohimbine in the management of
impotence shows a delayed action which is inconsistent with
its short apparent half life and thus its activity may reside in
possible metabolites that can display a biological half life long-
er than that of the parent drug. Two of these metabolites were
identiﬁed as 10- and 11-hydroxy yohimbine by the normal
phase HPLC method.7
Different methods were adopted for analyzing of yohim-
bine hydrochloride, including spectroscopic,8–10 voltammet-
ric,11 polarographic,12 chemiluminometric methods.13 Other
techniques were reported, such as TLC,14 HPLC15–18 and gas
chromatography.19
The ICH-guidelines20 require performing stress-testing of
the drug substance that can help in identifying the likely deg-
radation-products, also can be useful in establishing the degra-
dation-pathways and validating the stability-indicating power
of the analytical procedures used.
All the reported literatures were not involving the use of
either derivative or derivative-ratio spectrophotometric meth-
ods for determination of yohimbine hydrochloride in pharma-
ceutical preparations. In the present work derivative and
derivative ratio spectrophotometric methods were successfully
developed as simple, rapid, accurate and sensitive stability
indicating methods for determination of yohimbine hydrochlo-
ride in pharmaceutical preparations. Moreover, simple
isocratic high performance liquid chromatographic method
was also developed, which can be used for the routine quality
control analysis of these drugs in raw material and pharmaceu-
tical formulations and for stability studies.
2. Materials and methods
2.1. Chemicals and reagents
2.1.1. Pure standard
Yohimbine hydrochloride was kindly supplied by Al-Amriya
Pharmaceuticals (Alexandria-Egypt) its purity was found to
be 100.08 ± 1.203 according to ofﬁcial HPLC method.21
2.1.2. Pharmaceutical dosage forms
Yohimbex tablet: Batch No. 910508, manufactured by Al-
Amriya Pharmaceuticals (Alexandria-Egypt). Each tablet
contains 5.4 mg (yohimbine hydrochloride).2.1.3. Chemicals and reagents
All chemicals and reagents used through this work are of spec-
troscopic and chromatographic analytical grade. Acetonitrile,
Methanol, methylene chloride and bi-distilled water (Riedel-
dehaen, Sigma–Aldrich, Germany), orthophosphoric acid
and triethylamine (BDH, Poole, UK). 0.01 M, 1.0 M hydro-
chloric acid (E. Merck, Durmstoolt, Germany), 0.01 M, 2 M
and aqueous, sodium hydroxide: (BDH), 1 M, 2 M aqueous,
sulfuric acid (Adwic, Egypt), 33% ammonium hydroxide
(Adwic, Egypt).
2.2. Instruments
A double-beam Shimadzu (Japan) UV-VIS Spectrophotometer
(UV-1601 PC), model TCC-240 A; connected to an IBM com-
patible computer and HP 695 C DeskJet printer is used. The
bundled software is UVPC personal spectroscopy software ver-
sion 3.7 (Shimadzu). The spectral bandwidth is 2 nm and the
wavelength scanning speed was 280.0 nm/min. The absorption
spectra of the reference and the test solutions are recorded in
1.0-ml quartz cells at 25.0 C, using ‘Dk= 4 nm and scaling
factor of 10 for computing ﬁrst derivative (D1)’ and ‘Dk= 8 nm
and scaling factor of 100 for second (D2) one
- A (Jenway 3510, UK) pH-meter, equipped with combined
glass electrode was used for pH adjustment.
- The HPLC (Agilent Hewlett Packard series) instrument
was equipped with a model series 1100 pump, manual
injector Agilent 1100 series, 20 ll loop and a UV-visible
wavelength detector Agilent 1100 series. The chromato-
graphic separation was performed using (150 · 4.6 mm
I.D.) Agilent eclipse XDB C18 column (5 lm particle size)
at ambient temperature. Ultrasonic vibrator, (J.P Selecta
S-a; CD 300513 Espain). Disposible membrane ﬁlters,
0.45 lm, (Agilent 3150-0576) were used.
- UV illumination, 8-watt lamp.
- TLC silica gel 60F254 plates (E.Merck, Germany).
2.3. Standard solutions
2.3.1. Standard solution of the studied drug
Standard solutions of (yohimbine hydrochloride) having con-
centration of (1.0 mg/ml) and 0.1 mg/ml, in water are used.
2.3.2. Standard solution of degradates
2.3.2.1. Standard working solution for acid and alkaline-
degradates. Twenty-ﬁve microgram of pure drug was reﬂuxed
with either 25 ml of 1.0 M NaOH or 1.0 M HCl in a boiling
water bath for 1 or 2 h, respectively. Then cooled, neutralized
and diluted to 25 ml with water to obtain stock solution
labeled to contain 1 mg/ml of acid or alkaline degradate of
yohimbine hydrochloride. Its solution was diluted with water
to obtain 0.1 mg/ml degradate to be used in spectrophotomet-
ric method.
2.3.2.2. Standard working solution for photo-degradate. Ten
microgram of pure drug in 10 ml of 1.0 M H2SO4 was exposed
to UV-lamp set at 254 nm for 2 h then cooled, neutralized with
2.0 M NaOH and diluted to 10 ml with water to obtain stock
solution labeled to contain 0.1 mg/ml of photo-degradate.
Validated methods for determination of yohimbine hydrochloride in the presence of its degradation products 69Complete degradation was checked by TLC using silica gel
60F254 plates and a developing solvent system of methylene
chloride, methanol, and ammonium hydroxide in a ratio of
(90:14:1 by volume).15
2.4. Laboratory prepared mixtures
Solutions containing different ratios of yohimbine hydrochlo-
ride and its degradate were prepared to contain 10–90% of the
degradates.
2.5. Procedures
2.5.1. Spectrophotometric methods
2.5.1.1. Derivative spectrophotometric method (Dn). From
working standard solution of yohimbine hydrochloride,
aliquots were transferred into a series of 50 ml volumetricFigure 1 Zero order absorption spectra of 10 lg/ml of yohimbine H
hydrochloric acid as a blank.
Figure 2 Zero order absorption spectra of 10 lg/ml of yohimbine H
hydrochloric acid as a blank.ﬂasks, and diluted to volume with 0.01 M HCl to obtain a con-
centration range of 4.0–20.0, 2.0–20.0 and 2.0–20.0 lg/ml,
respectively. The values of ﬁrst (D1) and second (D2) derivative
spectrophotometry amplitudes at 291.20 and 233.4 nm (Zero-
crossing of alkaline-degradate) and at 232.6 and 289.4 nm
(Zero-crossing of photo – degradate) were then computed,
plotted versus corresponding concentrations; and the regres-
sion equations were then computed, respectively.
2.5.1.2. Derivative ratio spectrophotometric method (DRn). Ali-
quots from working standard solution of the drug (0.1 mg/ml)
were transferred into a series of 50 ml volumetric ﬂasks, and
diluting to volume with 0.01 M HCl to obtain a concentration
range of 2.0–18.0 lg/ml, 2.0–20.0 lg/ml and 2.0–20.0 lg/ml,
respectively. The spectra of acid, alkaline and photo-degradate
solutions, each having concentration 2.0 lg/ml were scanned
and stored in the instrument PC as devisors. The spectra ofCl (––) and 10 lg/ml of its alkaline degradate (– –) using 0.01 M
Cl (––) and of 10 lg/ml of its photodegradate (– –) using 0.01 M
Figure 3 Zero order absorption spectra of 10 lg/ml of yohimbine HCl (––) and 10 lg/ml of its acid degradate (– –) using 0.01 M
hydrochloric acid as a blank.
Figure 4 First derivative absorption spectra of 10 lg/ml yohimbine HCl (––) and 10 lg/ml its alkaline degradate (. . .. . .).
70 M. Farouk et al.yohimbine hydrochloride were divided by each devisor’s spec-
trum, then the ﬁrst derivative of the ratio spectra (DR1) was
computed and the peak amplitudes measured at 232.8 and
250.6 nm in case of acid degradate, at 266.2 nm for alkaline
degradate and 228.4 and 265.8 nm in case of photodegradate
and plotted versus concentrations, then the regression equa-
tions were computed, respectively.
2.5.1.3. Chromatographic method. A C18 (4.6 · 150 mm, 5 lm)
column, water and methanol in a ratio of 55:45 V/V containing
0.5% aqueous triethylamine at a ﬂow rate of 1 ml/min as
degassed and ﬁltered mobile phase, and UV detection at
270 nm, were the adopted chromatographic conditions. An
aliquot of yohimbine hydrochloride stock standard solution
(0.1 mg/ml) into a series of 50 ml volumetric ﬂasks and diluted
to volume with the mobile phase to obtain a concentration
range of 2.0–12.0 lg/ml. Twenty microliter volume from each
solution was injected in triplicate, the average peak area ob-tained for each concentration was plotted versus concentration
and the regression equation was then computed.
2.6. Assay of the pharmaceutical preparations Yohimbex
tablets
Twenty tablets were accurately weighed and ﬁnely powdered.
A portion of the powder equivalent to 10.0 of yohimbine
hydrochloride was accurately weighed, and the procedures
mentioned under (Section 2.5.1 and 2.5.2) were adopted,
respectively.
3. Results and discussion
The International Conference on Harmonization (ICH) guide-
line entitled ‘‘stability testing of new drug substances and prod-
ucts’’ requires the stress testing to be carried out to elucidate the
inherent stability characteristics of the active substance.20
Figure 5 Second derivative absorption spectra of 10 lg/ml of yohimbine HCl (––––) and 10 lg/ml of its alkaline degradate (– –).
Figure 6 First derivative absorption spectra of 10 lg/ml of yohimbine HCl (––) and of 10 lg/ml of its photodegradate (. . .. . .).
Figure 7 Second derivative absorption spectra of 10 lg/ml of yohimbine HCl (––) and of 10 lg/ml of its photodegradate (– –).
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Figure 9 First derivative of the ratio spectra of yohimbine HCl (2.0–20.0 lg/ml) and its acid degradate using 2.0 lg/ml as a divisor and
0.1 M hydrochloric acid as a blank.
Figure 10 First derivative of the ratio spectra of yohimbine HCl (2.0–20.0 lg/ml) and its photodegradate using (2.0 lg/ml) as a divisor
and 0.01 M hydrochloric acid.
Figure 8 First derivative of the ratio spectra of yohimbine HCl (2.0–20.0 lg/ml) and its alkaline degradate using 2.0 lg/ml as a divisor
and 0.01 M hydrochloric acid as a blank.
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Figure 11 Scanning proﬁle of HPLC chromatogram of 10 lg/ml of yohimbine HCl using ultraviolet detection at 270 nm .
Figure 12 HPLC chromatogram of yohimbine HCl (a) and its alkaline degradates (b, c), each of (10.0 lg/ml) using ultraviolet detection
at 270 nm.
Validated methods for determination of yohimbine hydrochloride in the presence of its degradation products 73Yohimbine hydrochloride was reported to undergo acidic,
alkaline hydrolysis22,23 and photodegradation.24–26 Thus in this
work pure yohimbine hydrochloride was reﬂuxed with 1 M
HCl for 1hr, 1 M NaOH for 2 h and exposed to UV-radiation
for 2 h in 2 M H2SO4 the neutrally hydrolyzed solution was
identiﬁed by TLC using silica gel 60F254 and a developing
system of methylene chloride: methanol: ammonium hydroxide
in a ratio (90:14:1 by volume). Complete hydrolysis was con-
ﬁrmed by a single spot for acid, alkaline and photodegradate
with consequent disappearance of drug spot.
3.1. Method development
3.1.1. Spectrophotometric method
The zero-order absorption spectra of yohimbine hydrochloride
and its alkaline, photo and acidic degradation products
showed severe overlapping, Figs. 1–3 respectively, which inter-
fere with the direct determination of yohimbine hydrochloride.Derivative spectrophotometry (Dn) is of great utility for
extracting both qualitative and quantitative information from
spectra composed of unresolved bands, and for eliminating the
effect of baseline shifts and baseline tilts by using the ﬁrst or
higher derivatives of absorbance with respect to wavelength.27
The present work is concerned with determination of
yohimbine hydrochloride in presence of its degradation prod-
ucts by using two simple, sensitive and rapid derivative (Dn)
and derivative ratio spectrophotometric (DRn) methods where
the investigated drug could be determined in presence of its
alkaline and photodegradation products by applying D1 and
D2 but failed to resolve the overlapping of the acid degradation
that could be successfully resolved by DRn technique.
3.1.2. Derivative spectrophotometric method (Dn)
In this method, yohimbine hydrochloride could be determined
in a concentration range of (4.0–20.0 lg/ml) in presence of
alkaline degradate by computing ﬁrst (D1) and second (D2)
Table 1 System suitability of developed HPLC method using ultraviolet detection at 270 nm for the determination of yohimbine HCl
in presence of its degradates.
System suitability parameters
of YOH.HCl in presence of:
Retention time
(min)
Capacity factor
(K0)
Selectivity
(a)
Number of theoretical plates
(N)
Resolution
(Rs)
Symmetry
Acid degradate 3.70 ± 0.027 1.64 1.30 3084 2.93 0.82
Alkaline degradate 3.70 ± 0.027 1.64 1.62 3084 4.04 0.82
Photodegradate 3.70 ± 0.027 1.64 3.77 3084 5.68 0.82
Figure 13 HPLC chromatogram of yohimbine HCl (a) and its acid degradate (b), each of (10.0 lg/ml) using ultraviolet detection.
Figure 14 Scanning proﬁle of HPLC chromatogram of yohimbine HCl (a) and its photodegradate (b) each of (10.0 lg/ml) using
ultraviolet detection at 270 nm.
74 M. Farouk et al.derivative spectrophotometry, where the amplitudes were mea-
sured at 291.20 (D1) and 233.4 (D2) nm, zero-crossing of alka-
line degradate. While selective determination of the cited drug
in presence of its photo degradate was achieved at 232.6 (D1)
where the degradate showed zero contribution and 289.4
(D2) nm where the degradate showed zero-crossing, as shown
in (Figs. 1–7).3.1.3. Derivative ratio spectrophotometric method (DRn)
The advantage of the derivative ratio spectral method may be
the chance of doing measurement in correspondence of peaks,
so there is a potential for greater sensitivity and accuracy.
While the main disadvantages of zero-crossing method for
resolving a mixture of components with overlapped spectra
are the risk of small drifts of the working wavelengths and
Table 2 Results of assay validation parameters of the proposed methods for the determination of pure yohimbine HCl.
Derivative
method
Derivative
ratio
HPLC
In
presence
of
Alkaline
degradate
Photo-
degradate
Alkaline
degradate
Photo-
degradate
Acid
degradate
All degradates
D1
291.2 nm
D2
233.4 nm
D1
232.6 nm
D2
289.4 nm
DD1
266.2 nm
DD1 228.4 nm DD1
265.8 nm
DD1
232.8 nm
DD1
250.6 nm
Linearity 2–20 lg/ml 2–18 lg/ ml 2–20 lg/ml 2–12 lg/ml
Slope 0.0171 0.0973 0.0456 0.0131 0.2886 0.2438 0.1276 1.0679 0.4192 23.23
Intercept 0.0046 0.0187 0.0053 0.0021 0.1233 0.0544 0.0487 0.124 0.0359 6.768
Correlation
coeﬃcient (r)
0.9999 1 0.9999 0.9999 0.9999 1 0.9999 1 0.9999 1
Standard error
of the slope
6.3 · 105 0.000171 0.000119 3.53 · 105 0.001123 0.000161 0.0004 0.001469 0.001192 0.016869
Conﬁdence limit
of the slope
0.016947–
0.017237
0.096903–
0.09769
0.045304–
0.045854
0.012965–0.013128 0.286026–
0.291205
0.243436–
0.244197
0.1266–0.128492 1.064544–1.071311 0.41643–
0.421927
23.18189–23.27556
Standard error
of the intercept
0.000781 0.002118 0.00148 0.000439 0.013936 0.001811 0.004502 0.018209 0.014791 0.131392
Conﬁdence limit
of the intercept
0.002825–
0.006428
0.013762–
0.023531
0.00192–
0.008746
0.001122–0.003145 0.091197–
0.15547
0.05867 to
(0.05011)
0.0593 to
(0.03801)
0.082011–
0.165989
0.001825–
0.070041
7.13275 to
(6.40314)
Standard error
of estimation
0.001144 0.003101 0.002167 0.000642 0.0204 0.002493 0.006197 0.026655 0.021652 0.141137
Accuracy
(mean ± SD)
99.85 ± 0.969 100.02 ± 0.429 100.05 ± 0.716 100.00 ± 0.800 99.96 ± 0.404 99.98 ± 0.125 99.95 ± 0.621 100.03 ± 0.642 99.91 ± 0.900 99.99 ± 0.092
Selectivity 99.24 ± 0.950 99.45 ± 0.745 100.64 ± 1.114 100.74 ± 1.209 99.60 ± 0.672 100.12 ± 0.537 100.16 ± 0.949 100.60 ± 1.012 100.91 ± 1.210
Precision
(RSD%)
Repeatability*
Intermediate
precision*
0.726
0.790
0.472
0.515
0.994
1.015
0.999
1.119
0.442
0.494
0.112
0.175
0.627
0.675
0.701
0.743
1.059
1.198
0.241
0.275
LOD** 0.12 lg/ml 0.13 lg/ml 0.1 lg/ml 0.06 lg/ml 0.25 lg/ml 0.13 lg/ml 0.20 lg/ml 0.09 lg/ml 0.07 lg/ml 0.17 lg/ml
LOQ** 0.36 lg/ml 0.40 lg/ml 0.31 lg/ml 0.19 lg/ml 0.77 lg/ml 0.40 lg/ml 0.60 lg/ml 0.28 lg/ml 0.21 lg/ml 0.52 lg/ml
* Average of three determination.
** Limit of detection and quantitation are determined via calculations. LOD= (SD of the response/slope) · 3.3. LOQ= (SD of the response/slope) · 10
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Table 3 Statistical comparison of the results obtained by the proposed methods and the ofﬁcial methods for the determination of yohimbine HCl in the presence of its degradates.
Derivative method Derivative
ratio
HPLC Oﬃcial
method*(21)
In
presence
of
Alkaline
degradate
Photo-
degradate
Alkaline
degradate
Photo-
degradate
Acid
degradate
All
degradates
D1
291.2 nm
D2
233.4 nm
D1
232.6 nm
D2
289.4 nm
DD1
266.2 nm
DD1
228.4 nm
DD1
265.8 nm
DD1
232.8 nm
DD1
250.6 nm
Mean 99.40 99.90 99.60 99.90 99.85 99.77 99.50 99.90 99.79 99.95 100.08
SD 1.097 0.875 0.977 0.998 0.824 0.969 1.027 0.695 0.912 0.520 1.203
RSD% 1.104 0.876 0.981 0.999 0.825 0.971 1.032 0.696 0.914 0.520 1.202
n 10 10 10 10 10 10 10 10 10 5 5
Variance 1.203 0.766 0.955 0.996 0.679 0.939 1.055 0.483 0.832 0.270 1.447
Student’s t-test 1.101** (2.160) 0.342** (2.160) 0.842** (2.160) 0.320** (2.160) 0.447** (2.160) 0.539** (2.160) 1.175** (2.160) 0.379** (2.160) 0.527** (2.160) 0.229** (2.306)
F-value 1.203** (3.633) 1.889** (3.633) 1.515** (3.633) 1.453** (3.633) 2.131** (3.633) 1.541** (3.633) 1.371** (3.633) 2.995** (3.633) 1.739** (3.633) 5.359** (6.388)
* HPLC method using water: dibasic sodium phosphate dehydrate: monobasic potassium phosphate (335:100:50 by volume), containing 4 gm of sodium dodocyl suphate is added, then 285 ml
acetonitrile is added.
** The values between parentheses are the corresponding theoretical values of t and F at the 95% conﬁdence level.
Table 4a Results obtained for the analysis of laboratory prepared mixtures containing different ratios of yohimbine hydrochloride and its degradates by derivative and derivative ratio
methods.
Intact (lg/ml) Method Derivative method Derivative ratio
In presence of Alkaline degradate Photo-degradate Alkaline degradate Photo-degradate Acid degradate
Degradate (lg/ml) D1 291.2 nm D2 233.4 nm D1 232.6 nm D2289.4 nm DD1 266.2 nm DD1 228.4 nm DD1 265.8 nm DD1 232.8 nm DD1 250.6 nm
10.00 1.00 98.90 99.47 100.64 100.78 99.45 100.24 100.16 100.60 101.03
10.00 3.00 100.64 100.60 99.78 98.74 98.80 99.24 99.06 99.71 99.86
10.00 5.00 98.56 99.34 98.96 100.08 99.18 99.87 99.40 99.47 99.04
10.00 7.00 98.62 99.84 100.94 101.70 99.89 100.09 100.02 100.22 101.52
10.00 9.00 100.24 99.02 101.80 101.06 99.50 100.48 100.64 101.75 101.97
10.00 10.00 98.47 98.40 101.74 102.10 100.75 100.80 101.73 101.86 102.01
Mean ± SD 99.24 ± 0.950 99.45 ± 0.745 100.64 ± 1.114 100.74 ± 1.209 99.60 ± 0.672 100.12 ± 0.537 100.16 ± 0.949 100.60 ± 1.012 100.91 ± 1.210
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Table 4b Results obtained for the analysis of laboratory prepared mixtures containing different ratios of yohimbine hydrochloride and its photodegradate by the proposed high
performance liquid chromatographic method.
Sample No. Intact drug (lg/ml) Photodegradate (lg/ml) Recovery%*
1 10.00 2.00 99.63
2 10.00 4.00 100.20
3 10.00 6.00 99.59
4 10.00 8.00 99.92
5 10.00 10.00 99.19
Mean ± SD 99.71 ± 0.379
* Average of ﬁve determinations.
Table 5 Quantitative determination of yohimbine hydrochloride in pharmaceutical preparation and application of standard addition technique by the proposed methods.
Pharmaceutical
preparation
Taken (lg/ml) Derivative method Derivative ratio HPLC
alkaline degradate photo-
degradate
alkaline
degradate
photo-
degradate
acid
degradate
All
degradates
D1
291.2 nm
D2
233.4 nm
D1
232.6 nm
D2
289.4 nm
DD1
266.2 nm
DD1
228.4 nm
DD1
265.8 nm
DD1
232.8 nm
DD1
250.6 nm
Found%± SD
Yohimbex tablets
claimed to contain
5.4 mg YOH.HCl/tablet
(Batch No. 910508)
5.00 99.40 ± 1.097 99.90 ± 0.875 99.60 ± 0.977 99.90 ± 0.998 99.85 ± 0.824 99.77 ± 0.969 99.50 ± 1.027 99.90 ± 0.695 99.79 ± 0.912 99.95 ± 0.520
Standard addition technique
Mean%± SD 99.58 ± 1.010 100.27 ± 0.501 100.36 ± 0.785 100.25 ± 0.808 99.70 ± 0.462 100.27 ± 0.590 99.64 ± 0.961 99.78 ± 0.222 99.72 ± 0.517 99.87 ± 0.249
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Table 6 Values of the slopes, intercepts, and regression
coefﬁcient of the Kobs versus sulfuric acid plots at different
and concentration.
Slope Intercept Regression
coeﬃcient (r)
Breakdown of intact 0.0943 0.0665 0.9987
Formation of degradate 0.0494 0.0672 0.9988
78 M. Farouk et al.the circumstance that the working wavelengths generally do
not fall in correspondence of peaks of the spectrum. This
particularly pronounced disadvantage when the slope of the
spectrum is very high with consequent loss of accuracy and
precision and the working wavelength is in proximity of the
base of the spectrum, which causes poor sensitivity.28
The main instrumental parameter conditions were opti-
mized for a reliable determination of the cited drug. Different
divisor concentrations of degradates were examined to select
an appropriate concentration which was found to be 2 lg/ml
for each degradate as the ﬁrst derivative of the ratio spectra
(DR1) was measured at 232.8 and 250.6 in presence of acidic
degradate, at 266.2 in presence of alkaline degradates and at
228.4 and 265.8 nm in presence of photo degradates, permit-
ting the selective determination of intact YOH. HCl in a
concentration range of 2.0–18.0 lg/ml, 2.0–20.0 lg/ml and
2.0–20.0 lg/ml, respectively, as shown in (Figs. 8–10), where
no noise was observed from the divisor.
3.1.4. Chromatographic method
The separation of yohimbine hydrochloride from its degradates
was performed on C18 (4.6 · 150 mm, 5 lm) column. The
proportion of the mobile phase components was optimized to
reduce each of retention time and tailing to enable good resolu-
tion from degradates. At high acetonitrile ratio, retention time
of different components decreased but with excessive tailing of
its peak. High resolution was obtained by using water and
methanol in a ratio of (55:45 v/v) containing 0.5% triethyl-
amine with a ﬂow rate of 1 ml/min as a mobile phase and
detection at 270 nm, where the maximum sensitivity was
obtained. The average retention time was 3.70 ± 0.027 min
for 10 replicates as shown in (Figs. 11–14), system suitability
was shown in [Table 1].
3.1.5. Method validation
ICH guidelines29 for validationmethodwere followed, where all
validation parameters were shown in (Table 2). All the obtained
results were statistically compared to the ofﬁcial method21 and
no signiﬁcant differences were found Table 3), respectively.
3.1.6. Speciﬁcity
Yohimbine hydrochloride was determined in solutions con-
taining different ratios of intact drug and its degradates each
separately (10–90%), by the proposed spectrophotometric
and chromatographic methods, as shown in (Tables 4a and
b) where, the recovery% and R.S.D. proved high speciﬁcity
of the adopted method.
3.1.7. Standard addition technique
To check the validity of the proposed methods, the standard
addition method was applied by adding yohimbine hydrochlo-
ride to the previously analyzed Yohimbex tablets. The recov-ery was calculated by comparing the concentration obtained
from the spiked samples with that of the pure drug. The results
of analysis of the commercial tablets and the standard addition
technique are shown in (Table 5) suggested that there is no
interference from any excipients, which are normally present
in tablets (see Table 6).
4. Conclusion
The proposed methods are accurate, precise and speciﬁc where
yohimbine hydrochloride can be determined in bulk powder,
in laboratory prepared mixtures with different ratios of its
degradates, and in pharmaceutical preparations without any
interference from common excipients present. ICH guidelines
were followed throughout the study for method validation
and stress testing, and the suggested methods can be applied
for routine quality control analysis and stability studies.
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